News | September 10, 2025
Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Subscribe To Our Newsletter & Stay Updated
